Merck KGaA Pins Cladribine Hopes On Ongoing Studies After "Complete Response" Letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck KGaA is hoping data from already completed and ongoing studies will satisfy FDA's need to better understand the risk-benefit profile for its oral multiple sclerosis therapy cladribine, after the agency issued a "complete response" March 2.